CAR-T therapies, which involve genetically modifying a patient's own T cells to recognize and attack cancer cells, are transforming cancer treatment. Researchers are now improving their effectiveness and safety, while also exploring their use outside hematological malignancies, enabling a broader range of applications.
Leveraging a CDMO's expertise is a crucial step for early-stage biotech companies looking to advance toward clinical proof of concept. Review what a cell therapy CDMO will do to demonstrate that not only are they strong and capable but they are also a true partner in what will be the most important years of your company's journey to success.
Pharmaceutical companies face pressure to balance cost and quality and to prioritize speed while identifying and mitigating risks that may increase costs in the long run. Examine considerations to help you strike the right balance to accelerate the delivery of transformative therapies while maintaining safety and upholding efficacy standards.
We have a proven track record of successfully transferring, developing, and manufacturing GMP drug products for use in clinical trials. Learn more about our capabilities and leadership team.
